NextCell Pharma AB (NXTCL) - Cash Flow Conversion Efficiency

Latest as of August 2025: -0.162x

Based on the latest financial reports, NextCell Pharma AB (NXTCL) has a cash flow conversion efficiency ratio of -0.162x as of August 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.77 Million ≈ $-1.16 Million USD) by net assets (Skr66.39 Million ≈ $7.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NextCell Pharma AB (NXTCL) total market value for the company's overall valuation and market capitalisation.

NextCell Pharma AB - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how NextCell Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

NextCell Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NextCell Pharma AB ranked by their cash flow conversion efficiency. See NXTCL operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Solueta Co Ltd KQ:154040	-0.026x
KR Motors Co. Ltd. KO:000040	-0.069x
Greencore Group LSE:GNC	0.221x
NPK Co.Ltd KQ:048830	0.058x
All In FutureTech Alliance Inc. NASDAQ:AIFA	-0.020x
Cheetah Holdings Bhd KLSE:7209	0.136x
Canadian North Resources Inc. V:CNRI	0.006x
Tellusgruppen AB ST:TELLUS	0.738x

Annual Cash Flow Conversion Efficiency for NextCell Pharma AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of NextCell Pharma AB from 2015 to 2025. View NXTCL stock price and chart for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-08-31	Skr66.39 Million ≈ $7.14 Million	Skr-38.86 Million ≈ $-4.18 Million	-0.585x	-4.75%
2024-08-31	Skr67.60 Million ≈ $7.27 Million	Skr-37.78 Million ≈ $-4.07 Million	-0.559x	+3.43%
2023-08-31	Skr75.73 Million ≈ $8.15 Million	Skr-43.83 Million ≈ $-4.72 Million	-0.579x	-100.73%
2022-08-31	Skr115.54 Million ≈ $12.43 Million	Skr-33.31 Million ≈ $-3.58 Million	-0.288x	-69.19%
2021-08-31	Skr150.09 Million ≈ $16.15 Million	Skr-25.58 Million ≈ $-2.75 Million	-0.170x	+76.44%
2020-08-31	Skr26.22 Million ≈ $2.82 Million	Skr-18.96 Million ≈ $-2.04 Million	-0.723x	+24.99%
2019-08-31	Skr22.96 Million ≈ $2.47 Million	Skr-22.13 Million ≈ $-2.38 Million	-0.964x	+64.13%
2018-08-31	Skr5.04 Million ≈ $542.53K	Skr-13.55 Million ≈ $-1.46 Million	-2.688x	-246.01%
2017-08-31	Skr19.07 Million ≈ $2.05 Million	Skr-14.82 Million ≈ $-1.59 Million	-0.777x	+52.74%
2016-08-31	Skr6.76 Million ≈ $728.00K	Skr-11.12 Million ≈ $-1.20 Million	-1.644x	-106.93%
2015-08-31	Skr9.77 Million ≈ $1.05 Million	Skr-7.76 Million ≈ $-835.27K	-0.794x	--

About NextCell Pharma AB

ST:NXTCL Sweden Biotechnology

Market Cap

$12.83 Million

Skr119.19 Million SEK

Market Cap Rank

#26508 Global

#555 in Sweden

Share Price

Skr1.07

Change (1 day)

+0.00%

52-Week Range

Skr0.67 - Skr1.69

All Time High

Skr29.60